Skip to content
    Piper Heartland Healthcare Capital logo

    Piper Heartland Healthcare Capital

    Minneapolis, Minnesota, United StatesFounded 2020
    www.pipersandler.com/alternative-asset-management/healthcare-funds
    Healthcare

    Piper Heartland Healthcare Capital is a private equity and buyout fund managed by Piper Sandler, focused on innovative healthcare companies with near-term public markets prospects. The firm's inaugural fund, Piper Heartland Healthcare Crossover Fund I, closed with over $200 million in committed capital.

    71% of their portfolio is in Biotech & Life Sciences. Average disclosed round size is $162.9M (across 20 rounds with reported amounts).

    Find people at Piper Heartland Healthcare Capital on Goldilocks AI

    Portfolio

    16

    Fund Size

    $200M

    Top Stage

    Series B

    Last 12 Mo

    0

    Team

    AE

    Ahmad El Naggar

    Director, Piper Heartland Healthcare Capital

    TH

    Trent Holland

    Vice President, Piper Heartland Healthcare Capital

    JS

    John Snodgrass

    Associate, Piper Heartland Healthcare Capital

    Portfolio Breakdown

    Stage Distribution

    Sector Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    21 investments
    CompanyRoundAmountDate
    OrganOx logoOrganOxGrowth$160MMay 2025
    Arbor Biotechnologies logoArbor BiotechnologiesSeries C$73.9MMar 2025
    Kardium logoKardiumUnknown$250MJan 2025
    Alentis Therapeutics logoAlentis TherapeuticsSeries D$181.4MNov 2024
    AAlentisSeries D$181.4MNov 2024
    Avencell logoAvencellSeries B$112MOct 2024
    Endeavor Biomedicines logoEndeavor BiomedicinesUnknown$132.5MApr 2024
    Alumis logoAlumisSeries C$259MMar 2024
    ProfoundBio logoProfoundBioSeries B$112MFeb 2024
    Maze Therapeutics logoMaze TherapeuticsUnknown$115MJan 2024
    Alentis Therapeutics logoAlentis TherapeuticsSeries D$181.4MJan 2024
    AAlentisSeries D$181.4MJan 2024
    Endeavor Biomedicines logoEndeavor BiomedicinesSeries B$101MFeb 2022
    Arbor Biotechnologies logoArbor BiotechnologiesSeries B$215MNov 2021
    Sonoma Biotherapeutics logoSonoma BiotherapeuticsSeries B$265MAug 2021
    Artios logoArtiosSeries C$153MJul 2021
    AArtios Pharma LimitedSeries C$153MJul 2021
    Arbor Biotechnologies logoArbor BiotechnologiesSeries B$215MJan 2021
    Artios logoArtiosSeries C——
    Bicara Therapeutics logoBicara TherapeuticsSeries B$108M—
    BBicaraSeries B$108M—

    Top Co-Investors

    RA Capital Management9 shared
    Deep Track Capital8 shared
    Ally Bridge Group8 shared
    Omega Funds8 shared
    OrbiMed6 shared
    Avidity Partners6 shared
    The Invus Group, LLC6 shared
    Longitude Capital6 shared
    T. Rowe Price5 shared
    ARCH Venture Partners5 shared
    Frazier Life Sciences5 shared
    Surveyor Capital4 shared
    TCG Crossover4 shared
    Logos Capital4 shared
    Frazier Healthcare Partners4 shared
    Bpifrance4 shared
    Jeito Capital4 shared
    Novo Capital4 shared
    Temasek Holdings (Private) Limited3 shared
    Vertex Pharmaceuticals3 shared

    Last updated: 20 October 2026